| Project/Area Number |
22K18187
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 90110:Biomedical engineering-related
|
|---|
| Research Institution | Shibaura Institute of Technology |
|---|
Principal Investigator |
Aaryashree 芝浦工業大学, 工学部, 准教授 (20908165)
|
|---|
| Project Period (FY) |
2022-04-01 – 2025-03-31
|
| Project Status |
Granted (Fiscal Year 2023)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2024: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2023: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2022: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | Vancomycin / MIP-carbon paste / TDM / vancomycin / MIP carbon paste / MIP / disposable sensor |
|---|
| Outline of Research at the Start |
Point-of-care monitoring is important for the evaluation and prevention of toxic effects of antimicrobial drugs such as vancomycin (VCM). This project is aimed to develop a Molecularly imprinted polymer grafted carbon paste electrode for VCM sensor.
|
| Outline of Annual Research Achievements |
Our research has been dedicated to developing and optimizing a vancomycin (VCM) sensor for therapeutic drug monitoring (TDM) in whole blood. Initially, we faced significant challenges related to the reproducibility and stability of the molecularly imprinted polymer-grafted-carbon paste (MIP-CP) sensor. The sensor often lost sensitivity within three days, making it unsuitable for long-term use. Through extensive optimization, we successfully enhanced the reproducibility of the MIP-CP, ensuring consistent performance across different batches. This included refining the polymerization process and improving the uniformity of the carbon paste.
One of our major milestones was extending the sensor's stability. We achieved a long-term stability of one month in buffer saline and serum, a significant improvement from the previous two weeks in buffer saline and ten days in whole bovine blood. This was accomplished by addressing the sensor's chip base structure and optimizing the amperometric measurement mode.
These advancements have not only enhanced the sensor's performance but also demonstrated its potential for practical applications in TDM. Our research has been disseminated through presentations at three major conferences, contributing to the broader scientific community's understanding of VCM sensors. The improvements in reproducibility, stability, and sensitivity mark significant progress in our work, paving the way for future developments and applications in biomedical diagnostics and food safety monitoring.
|
| Current Status of Research Progress |
Current Status of Research Progress
1: Research has progressed more than it was originally planned.
Reason
Building on our previous efforts, we have continued to enhance the performance and stability of our vancomycin (VCM) sensor. Ensuring safe levels of antimicrobial drugs is imperative to prevent adverse effects, with Therapeutic Drug Monitoring (TDM) serving as a valuable tool in achieving this goal. Through further optimization, we have achieved significant improvements in the sensor's design and functionality.Key advancements include:
1. Reproducibility: We have refined the molecularly imprinted polymer-grafted-carbon paste (MIP-CP), achieving a high level of reproducibility across different batches.
2. Long-Term Stability: The long-term stability of the chip sensor has been significantly enhanced. We have successfully extended the stability to one month in buffer saline. In serum, stability has also reached one month, although stability at higher concentrations remains a challenge.
3. Enhanced Sensitivity: Improvements in the chip base structure have led to better sensitivity and overall performance of the sensor.
These advancements represent a notable improvement over previous iterations. The stability of the sensor in various environments demonstrates its potential for practical applications in therapeutic drug monitoring. Our commitment to refining its capabilities has been reflected in these significant milestones. These developments have been effectively communicated through conferences and short communications, showcasing the progress and potential of our sensor technology.
|
| Strategy for Future Research Activity |
Our future work will focus on improving the sensor's performance at higher vancomycin concentrations to ensure stability and accuracy across a broader range of conditions. Additionally, we are preparing for the next clinical trial batch to validate the sensor's efficacy and reliability in real-world medical settings. These efforts aim to enhance the practical applicability of our sensor, paving the way for its integration into routine therapeutic drug monitoring.
|
